Imaging Technique Helps Early Detection of Prostate Cancer Recurrence and Aids Radiation Therapy

by Anjali Aryamvally on February 3, 2018 at 11:20 AM

Earlier identification of the location of prostate cancer recurrence after radical prostatectomy could help guide salvage radiotherapy, according to new study from the University of California Los Angeles. The study utilizes PET/CT with gallium-68 prostate-specific membrane antigen (68Ga-PSMA-11) to locate the cancer recurrence location and is published in The Journal of Nuclear Medicine.

Prostate cancer biochemical recurrence occurs in 20 to 80 percent of patients within 10 years after radical prostatectomy and is difficult to treat. Salvage radiotherapy is the main option for treatment, but the imaging modalities currently used are not sensitive enough to identify the location of recurrence until it is too late, leading to a "best-guess" approach for targeting the radiotherapy.

Brachytherapy for Prostate Cancer

Learn about two different types of brachytherapy used for treating prostate cancer. Get information on the latest advances in the field.

‘Earlier pinpointing of prostate cancer recurrence locations after radical prostatectomy means that PSMA PET/CT could help guide salvage radiotherapy, resulting in more effective treatment for many patients.’

Tweet it Now

"Based on European data, we believe that PSMA PET/CT, an imaging technique that is not yet approved by the U.S. Food and Drug Administration, is sufficiently sensitive to detect and localize the recurrent prostate cancer early enough to potentially guide salvage radiotherapy," explains Jeremie Calais, MD, at UCLA. "The first sign of prostate cancer recurrence is a rising PSA. For salvage radiotherapy to be successful, it should be initiated before the PSA rises above 1 ng/mL, and ideally, closer to 0.2 ng/mL or lower."

Study overview

The study included 270 well-documented patients from databases established at four institutions (UCLA and three in Germany: Technical University of Munich, Ludwig-Maximilians-University of Munich, and University of Essen). All patients had a biochemical recurrence of prostate cancer after radical prostatectomy but had not received prior radiotherapy. They underwent PSMA PET/CT at a serum PSA level of less than 1 ng/ml.

Decipher Test for Prostate Cancer

Decipher test a genomic test for prostate cancer that determines the aggressiveness of the cancer and helps in planning the treatment course for the cancer.

Nearly half (132 patients or 49 percent) had a positive PSMA PET/CT, and 52 (19 percent) had at least one PSMA-positive lesion that was not covered by the consensus clinical target volume (CTV). The two most common PSMA PET-positive lesion locations outside the consensus radiation fields were bone (23/52, 44 percent) and perirectal lymph nodes (16/52, 31 percent).

Calais points out, "Salvage radiotherapy is only curative if recurrent disease is completely encompassed by the radiotherapy fields. Therefore, in almost 20 percent of these patients, the addition of PSMA PET/CT would have a potentially major impact on the outcome of salvage radiotherapy."

He elaborates, "Visualizing sites of prostate cancer recurrence accurately, and early enough to guide therapy, enables truly precision radiation therapy. This is, in fact, the definition of individualized medicine. We believe that PSMA PET/CT imaging will ultimately be incorporated into the standard of care for prostate cancer patients with biochemical recurrence."

Toward that end, the suggested next step is a randomized imaging trial of salvage radiotherapy with or without PSMA PET/CT to investigate further its potential beneficial impact on treatment outcome.

Source: Eurekalert

Drugs for Prostate Cancer

Prostate cancer is the main cause of cancer death in men. One of the treatment method includes prescribing chemotherapeutic or hormonal drugs. These are prescribed depending on the type and stage of cancer.

<< How Social Media may Boost the Confidence of Young People in...

Low Muscle Strength- a Major Cause of ALS >>

External Beam Radiation Therapy for Prostate Cancer

In depth information about various types of external beam radiotherapy for treatment of prostate cancer. Radiotherapy is an alternative to surgical treatment such as radical prostatectomy.